Cali Biosciences
Jon Meisner is currently the VP of Clinical Development & Corporate Strategy at Cali Biosciences. Prior to their current role, Jon held positions such as Executive Director of Medical Affairs & Clinical Development at Innocoll Biotherapeutics, Executive Director of Clinical Development at DURECT Corporation, Sr. Medical Director at JLM MedCom Consulting, and Senior VP of Medical Director at Kane and Finkel. With a background in anesthesiology and degrees in MD, Physics, and Film Production, Jon has a diverse and extensive experience in the pharmaceutical and medical industries.
This person is not in any teams
This person is not in any offices
Cali Biosciences
Cali Biosciences is an international biopharmaceutical company dedicated to the research and development of innovative drugs. We have an international team of scientific research and management talents and is developing new drugs based on several patented technology platforms. We focus on the R&D of perioperative drugs. The product pipeline includes new drugs in the fields of anesthesia, analgesia, anti-inflammatory and anti-infection. In the future, we will also promote the commercialization of products to fully respond to the unmet market demand. The company focuses on the research and development of innovative drugs, with laboratories and offices in Shenzhen, China, and San Diego, USA, and a clinical development center in Shanghai, China. The company's main business is the R&D and production of innovative drugs, registration and application, as well as Sino-US market research, strategic operations and commercialization. The current product pipeline is consists of several modified new drugs based on the 505(b)(2) regulatory pathways. During the R&D process and upon completing the clinical trials, we seek approval from China, US and EU regulatory agencies and aiming at bringing innovative drugs in global markets. We are building a perioperative medication (anaesthesia, analgesia, anti-inflammatory, anti-infection) pipeline to meet the global unmet needs. At present, we have multiple clinical and pre-clinical stage drug candidates, the target market of the product pipeline is huge, and the clinical needs are clear. All the product pipeline is complex injection preparations with high technology patent threshold. Our goal is to serve patients and medical staff around the world, and our mission is to improve human survival and the quality of life.